ALDX Q4 2017 Earnings — Aldeyra Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ALDXAldeyra Therapeutics, Inc.

$290M

Q4 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$24.1T+149694047.9% YoY

Gross Profit

$24.1T100.0% margin

Operating Income

-$7M-0.0% margin

Net Income

-$7M-0.0% margin

EPS (Diluted)

$-0.36

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$592,172

Balance Sheet

Total Assets

$44M

Total Liabilities

$5M

Stockholders' Equity

$40M

Cash & Equivalents

$20M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$24.1T	$16M	+149694047.9%
Gross Profit	$24.1T	$16M	+149694047.9%
Operating Income	-$7M	-$5M	-51.5%
Net Income	-$7M	-$5M	-49.5%